Table of Contents:

1)        PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018

1a) PD-1 Receptor Antagonists:

• Approved and Marketed PD-1 Antagonists 
• Specific PD-1 Antagonists in Clinical Development for Regulated Markets
• Bispecific PD-1 Antagonists in Clinical Development for Regulated Markets
• Specific PD-1 Antagonists in Clinical Development for Less Regulated Markets
• Specific PD-1 Antagonists in Non- or Pre-Clinical Development
• Bispecific PD-1 Antagonists in Non- or Pre-Clinical Development

1b) PD-L1 Inhibitors:

• Approved and Marketed PD-L1 Inhibitors 
• Specific PD-L1 Inhibitors in Clinical Development for Regulated Markets
• Bispecific PD-L1 Inhibitors in Clinical Development for Regulated Markets
• Specific PD-L1 Inhibitors in Clinical Development for Less Regulated Markets
• Specific PD-L1 Inhibitors in Non- and Preclinical Development
• Bi-and Multi-Specific PD-L1 Inhibitors in Non- and Preclinical Development

2)        Corporate PD-1 and PD-L1 Checkpoint Inhibitor R&D Pipelines